KR102028850B1 - 히스톤 디아세틸라아제의 저해제들로서 유용한 거대고리 화합물들 - Google Patents

히스톤 디아세틸라아제의 저해제들로서 유용한 거대고리 화합물들 Download PDF

Info

Publication number
KR102028850B1
KR102028850B1 KR1020187018653A KR20187018653A KR102028850B1 KR 102028850 B1 KR102028850 B1 KR 102028850B1 KR 1020187018653 A KR1020187018653 A KR 1020187018653A KR 20187018653 A KR20187018653 A KR 20187018653A KR 102028850 B1 KR102028850 B1 KR 102028850B1
Authority
KR
South Korea
Prior art keywords
alkyl
delete delete
formula
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187018653A
Other languages
English (en)
Korean (ko)
Other versions
KR20180081153A (ko
Inventor
슈에동 리우
앤드류 제이 필립스
다나 언절먼노바
크리스토퍼 지 나스베척
간 장
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 filed Critical 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트
Publication of KR20180081153A publication Critical patent/KR20180081153A/ko
Application granted granted Critical
Publication of KR102028850B1 publication Critical patent/KR102028850B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020187018653A 2010-05-27 2011-05-26 히스톤 디아세틸라아제의 저해제들로서 유용한 거대고리 화합물들 Active KR102028850B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34897810P 2010-05-27 2010-05-27
US61/348,978 2010-05-27
PCT/US2011/038246 WO2011150283A1 (en) 2010-05-27 2011-05-26 Macrocyclic compounds useful as inhibitors of histone deacetylases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127033908A Division KR20130123301A (ko) 2010-05-27 2011-05-26 히스톤 디아세틸라아제의 저해제들로서 유용한 거대고리 화합물들

Publications (2)

Publication Number Publication Date
KR20180081153A KR20180081153A (ko) 2018-07-13
KR102028850B1 true KR102028850B1 (ko) 2019-10-04

Family

ID=45004403

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127033908A Abandoned KR20130123301A (ko) 2010-05-27 2011-05-26 히스톤 디아세틸라아제의 저해제들로서 유용한 거대고리 화합물들
KR1020187018653A Active KR102028850B1 (ko) 2010-05-27 2011-05-26 히스톤 디아세틸라아제의 저해제들로서 유용한 거대고리 화합물들

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020127033908A Abandoned KR20130123301A (ko) 2010-05-27 2011-05-26 히스톤 디아세틸라아제의 저해제들로서 유용한 거대고리 화합물들

Country Status (17)

Country Link
US (2) US8754050B2 (enExample)
EP (1) EP2575467B1 (enExample)
JP (1) JP5931850B2 (enExample)
KR (2) KR20130123301A (enExample)
CN (1) CN102946732B (enExample)
AU (1) AU2011258110B2 (enExample)
BR (1) BR112012030193B1 (enExample)
CA (1) CA2800958C (enExample)
DK (1) DK2575467T3 (enExample)
ES (1) ES2594500T3 (enExample)
HU (1) HUE030812T2 (enExample)
LT (1) LT2575467T (enExample)
MX (1) MX2012013507A (enExample)
PL (1) PL2575467T3 (enExample)
PT (1) PT2575467T (enExample)
RU (1) RU2565076C2 (enExample)
WO (1) WO2011150283A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391359B (zh) * 2011-11-17 2014-07-16 南京优科生物医药研究有限公司 组蛋白去乙酰化酶抑制剂及其合成方法和制药用途
CN103232474A (zh) * 2013-04-16 2013-08-07 中国药科大学 组蛋白去乙酰化酶抑制剂
CN103524598A (zh) * 2013-09-02 2014-01-22 上海冠宇生物医药科技有限公司 一类环肽类化合物、其制备方法、药物组合物及用途
TWI775203B (zh) * 2014-05-27 2022-08-21 美商昂克爾公司 製備環縮肽之方法
US10676504B2 (en) 2015-03-06 2020-06-09 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
CA2978730A1 (en) * 2015-03-06 2016-09-15 Colorado State University Research Foundation Synthesis and utility of new capgroup largazole analogs
CN105131082A (zh) * 2015-09-17 2015-12-09 广州康缔安生物科技有限公司 环肽类化合物及其应用
CN106674252B (zh) * 2015-11-11 2019-10-29 复旦大学 海洋天然产物环酯肽的氟代烯烃类似物、其制备方法和用途
HK1250948A1 (zh) 2016-05-20 2019-01-18 恩库勒公司 作为组蛋白脱乙酰酶抑制剂的大环硫代酸酯前体药物
CN107286223B (zh) * 2017-07-17 2019-12-20 湖北大学 一种用于检测组蛋白位点乙酰化的重组蛋白及其应用
CN111269245B (zh) * 2018-12-04 2021-08-27 杭州百新生物医药科技有限公司 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
US20220017520A1 (en) * 2018-12-19 2022-01-20 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
EP3941457A4 (en) 2019-03-21 2023-04-26 Merck Sharp & Dohme LLC HISTONE-DEACETYLASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF HIV INFECTION
KR102436309B1 (ko) * 2020-05-26 2022-08-25 연세대학교 산학협력단 암의 예방 또는 치료용 약학적 조성물
CA3205814A1 (en) * 2020-12-21 2022-06-30 Colorado State University Research Foundation Synthesis of structural analogs of largazole and associated compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128660A1 (en) 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
US20100029731A1 (en) 2008-07-17 2010-02-04 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8920304D0 (en) 1989-09-08 1989-10-25 Fujisawa Pharmaceutical Co Fr901375 substance and preparation thereof
KR20050059158A (ko) * 2002-08-30 2005-06-17 아스텔라스세이야쿠 가부시키가이샤 신규 뎁시펩타이드 화합물
MXPA05004738A (es) * 2002-11-12 2005-08-03 Alcon Inc Inhibidores de histona deacetilasa para tratar enfermedades degenerativas del ojo.
CA2670223A1 (en) * 2006-11-22 2008-05-29 Karus Therapeutics Limited Depsipeptides and their therapeutic use
GB0623388D0 (en) * 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
GB0715750D0 (en) * 2007-08-13 2007-09-19 Karus Therapeutics Ltd Chemical compounds
CA2721163A1 (en) * 2008-04-11 2009-10-15 University Of Florida Research Foundation, Inc. Macrocyclic compounds and methods of treatment
CN102391359B (zh) * 2011-11-17 2014-07-16 南京优科生物医药研究有限公司 组蛋白去乙酰化酶抑制剂及其合成方法和制药用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128660A1 (en) 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
US20100029731A1 (en) 2008-07-17 2010-02-04 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Research, 62(1), 4916-4921, 2002.

Also Published As

Publication number Publication date
AU2011258110A1 (en) 2013-01-10
US8754050B2 (en) 2014-06-17
CN102946732B (zh) 2014-11-26
KR20180081153A (ko) 2018-07-13
MX2012013507A (es) 2013-03-12
DK2575467T3 (en) 2016-09-26
CA2800958A1 (en) 2011-12-01
RU2565076C2 (ru) 2015-10-20
EP2575467B1 (en) 2016-07-06
CA2800958C (en) 2018-09-04
EP2575467A4 (en) 2014-10-15
WO2011150283A1 (en) 2011-12-01
BR112012030193B1 (pt) 2020-11-17
LT2575467T (lt) 2017-01-10
PL2575467T3 (pl) 2017-10-31
JP5931850B2 (ja) 2016-06-08
EP2575467A1 (en) 2013-04-10
HK1181613A1 (en) 2013-11-15
KR20130123301A (ko) 2013-11-12
RU2012157293A (ru) 2014-07-10
BR112012030193A2 (pt) 2015-09-29
AU2011258110B2 (en) 2015-07-16
PT2575467T (pt) 2016-10-14
ES2594500T3 (es) 2016-12-20
HUE030812T2 (en) 2017-05-29
JP2013528182A (ja) 2013-07-08
CN102946732A (zh) 2013-02-27
US20130203681A1 (en) 2013-08-08
US9422340B2 (en) 2016-08-23
US20150010541A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
KR102028850B1 (ko) 히스톤 디아세틸라아제의 저해제들로서 유용한 거대고리 화합물들
B Tsogoeva Recent progress in the development of synthetic hybrids of natural or unnatural bioactive compounds for medicinal chemistry
Tan Filamentous tropical marine cyanobacteria: a rich source of natural products for anticancer drug discovery
JP2023139183A (ja) ヒストンデアセチラーゼの阻害剤としての大環状分子のチオエステルプロドラッグ
Class et al. Patent application title: Macrocyclic Compounds Useful as Inhibitors of Histone Deacetylases Inventors: Xuedong Liu (Niwot, CO, US) Andrew J. Phillips (Guilford, CT, US) Dana Ungermannova (Houston, TX, US) Christopher G. Nasveschuk (Stoneham, MA, US) Christopher G. Nasveschuk (Stoneham, MA, US) Gan Zhang (Niwot, CO, US) Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO
HK1181613B (en) Macrocyclic compounds useful as inhibitors of histone deacetylases
HK40031377A (en) Thioester prodrugs of macrocycles as inhibitors of histone deacetylases

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180629

Application number text: 1020127033908

Filing date: 20121226

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180801

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190401

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180801

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190401

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190125

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20190701

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190625

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190401

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190125

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190927

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190927

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220818

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230822

Start annual number: 5

End annual number: 5